Foundation Funds Major Expansion of Gastric Cancer Registry
The Gastric Cancer Foundation has committed $257,856 to fund a transformative expansion of the Gastric Cancer Registry in 2021. The... Read More
Our Impact
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
Gastric Cancer Registry Prepares to Launch Innovative Data Portal
The Gastric Cancer Registry is the first comprehensive repository of clinical and genomic data pertaining to stomach cancer. Its chief... Read MoreFoundation-Funded Lab at MD Anderson Advances Discoveries in Peritoneal Carcinomatosis
About 45% of gastric cancer patients experience peritoneal carcinomatosis (PC), the spread of the cancer to the abdominal lining—a development... Read More
Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma
Bristol Myers Squibb’s Opdivo improved survival in previously untreated gastric cancer patients in a trial presented at ESMO20.
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
CARsgen Therapeutics was granted orphan drug designation by the US FDA for CAR-T Cells for the treatment of gastric and... Read More
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo were granted priority review by the FDA for Enhertu to treat HER2-positive gastric or gastroesophageal junction... Read MoreNew Grant Awarded to USC for Study of Epigenetic Targets in Gastric Cancer
Some gastric tumors have genetic abnormalities that can be directly targeted with drugs, such as HER2 mutations. But cancer is... Read MoreNew Foundation Grant to Dana-Farber for Study of “Chromosomal Instability” in Gastric Cancer
Gastric tumors with a genetic abnormality called microsatellite instability-high (MSI-H) can be treated with immune-targeted drugs, but there’s a much... Read More
Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer
Basilea Pharmaceutica has started a study of a drug that inhibits the cancer-driving protein FGFR. It will be studied alone... Read More
Association of malnutrition with geriatric assessment impairments and health‐related quality of life among older adults with gastrointestinal malignancies
Gastric cancer patients over age 60 face a high risk of malnutrition, which lowers their quality of life and leads... Read More
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
The FDA granted fast-track designation to Leap Therapeutics’ DKN-01, which blocks the DKK1 protein found in abundance in some gastric... Read More-
Enhertu now approved in Japan for gastric cancer
Enhertu from Daiichi-Sankyo is now approved in Japan for the treatment of HER2-positive gastric cancer. -
Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer
Leap Therapeutics and BeiGene have started dosing patients in a trial combining an anti-PD-1 antibody with the novel targeted drug... Read More 
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
In a recent trial, Keytruda was found to be as effective as chemotherapy in previously untreated gastric cancer patients, but... Read More
Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer
Laparoscopic surgery was equally effective as open surgery in gastric cancer patients in extending relapse-free survival periods, a recent study... Read More
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma
Combining Cyramza with IMFINZI® (durvalumab) was safe and effective in a small trial that included gastric cancer patients.
Pieris and Lilly enter into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 with Ramucirumab and Paclitaxel in Gastric Cancer
Pieris and Eli Lilly have partnered to test a combination of Cyramza, paclitaxel and Pieris’ novel bispecific antibody in HER2-positive... Read More
First US clinical trial testing efficacy of delivering aerosolized chemotherapy
City of Hope is recruiting patients with gastric cancer for a trial of a chemotherapy spray that can be delivered... Read More-
Immune Protein IL-17A Responsible for Lethal Side Effects of Gastric Cancer
Researchers in Japan discovered that the pro-inflammatory cytokine IL-17A plays a role in promoting peritoneal spread in gastric cancer, and... Read More -
Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and... Read More
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.